Detalhe da pesquisa
1.
HIV rebound in HIV controllers is associated with a specific fecal microbiome profile.
Eur J Immunol
; : e2350809, 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38727191
2.
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.
N Engl J Med
; 385(21): 1941-1950, 2021 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34706189
3.
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
N Engl J Med
; 382(12): 1124-1135, 2020 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32130806
4.
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
JAMA
; 327(13): 1236-1246, 2022 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35285853
5.
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1.
Clin Infect Dis
; 72(11): e815-e824, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33043969
6.
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Lancet
; 396(10246): 239-254, 2020 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32711800
7.
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Lancet
; 391(10123): 839-849, 2018 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29310899
8.
Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
AIDS Care
; 28(3): 401-8, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26489045
9.
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
J Infect Dis
; 212(1): 18-27, 2015 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25395187
10.
Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO Study.
Open Forum Infect Dis
; 11(1): ofad626, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38213637
11.
Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
HIV Clin Trials
; 14(5): 216-23, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24144898
12.
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.
Lancet HIV
; 10(8): e497-e505, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37451297
13.
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy.
AIDS
; 36(2): 195-203, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34652287
14.
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19.
Int J Infect Dis
; 122: 585-592, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35788416
15.
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy.
Sci Transl Med
; 13(599)2021 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34162752
16.
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Lancet HIV
; 8(4): e185-e196, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33794181
17.
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Lancet HIV
; 7(6): e389-e400, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32504574
18.
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Lancet HIV
; 6(6): e355-e363, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31068270
19.
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide.
AIDS
; 32(12): 1723-1725, 2018 07 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29794828
20.
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain.
PLoS One
; 13(1): e0190487, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29304154